TickerHumNYSE · Healthcare · Drug Manufacturers—General
AbbVie Inc. (ABBV)
As of Nov 11, 1:50 PM ET, AbbVie (ABBV) last traded at $292.92, down 0.33% on the day. Its TickerHum research score is 62/100 (above average). It reported revenue of $66.01B for the twelve months ending 2026-09-30, up 10.7% year over year, with a 32.2% operating margin.
Ratings
- Valuation: 46/100 — Strongest input: price / sales (ttm) 7.8x. Weakest: price / earnings (ttm) 50.4x.
- Growth: 76/100 — Strongest input: diluted eps growth (ttm, yoy) +340.2 %. Weakest: revenue growth (ttm, yoy) +10.7 %.
- Profitability: 79/100 — Strongest input: operating margin 32.2 %. Weakest: net margin 15.7 %.
- Financial health: 4/100 — Based on current ratio 0.87, cash / long-term debt 0.15.
- Momentum: 87/100 — Strongest input: 6-month return +40.4 %. Weakest: 1-year return +25.5 %.
- Attention: 50/100 — Strongest input: headlines in the last 7 days 46. Weakest: volume vs 3-month average 0.3x.
- Risk resilience: 82/100 — Strongest input: annualised volatility (1y) 25.4 %. Weakest: max drawdown (1y) -16.5 %.
- Data confidence: 95/100 — Strongest input: quote age (hours) 0 h. Weakest: inputs available 85 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $66.01B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 10.7% | TTM ending 2026-09-30 · 10-Q |
| Net income | $10.34B | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | $5.81 | TTM ending 2026-09-30 · 10-Q |
| Operating margin | 32.2% | TTM ending 2026-09-30 · 10-Q |
| Net margin | 15.7% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | $18.87B | TTM ending 2026-09-30 · 10-Q |
| Cash | $10.77B | as of 2026-09-30 · 10-Q |
| Long-term debt | $72.23B | as of 2026-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0001551152).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.